Kadence Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kadence Bio is a private, clinical-stage therapeutics company founded in 2020, developing small molecule drugs for sexual and mental health. Its lead asset, KH-001, is an on-demand oral treatment for premature ejaculation (PE) and has successfully completed Phase 1 safety studies as of Q3 2024. The company positions itself to address a significant intimacy gap and unmet medical need, as there are currently no FDA-approved pharmacological treatments for PE. Kadence Bio is a certified B-Corp and has participated in several accelerator programs, indicating a focus on social impact and venture backing.

Sexual HealthMental Health

Technology Platform

Focus on clinical development of on-demand, orally administered small molecule therapeutics for episodic conditions.

Opportunities

First-mover advantage in securing FDA approval for a pharmacological treatment for premature ejaculation, a large and untreated market.

The broader narrative of improving relationship health and closing the 'intimacy gap' could drive strong patient and prescriber engagement.

A successful lead program would provide capital and validation to advance the earlier-stage mood disorder pipeline.

Risk Factors

High dependency on the success of a single lead asset (KH-001) in unproven clinical and regulatory pathways for sexual health.

Future commercial success faces competition from established, low-cost off-label generic treatments and potential market resistance due to stigma.

As an early-stage private company, it faces significant financing risk to reach key clinical milestones.

Competitive Landscape

The premature ejaculation treatment landscape lacks any FDA-approved drugs, with current standard of care relying on off-label use of antidepressants (e.g., dapoxetine outside the US, other SSRIs) and topical anesthetics. Kadence Bio's primary competition is these generic alternatives and behavioral therapies. Its strategy is to differentiate through a dedicated, on-demand oral formulation seeking formal regulatory approval, which could offer improved labeling, marketing claims, and potentially better reimbursement compared to off-label options.

More companies in Small Molecule Drugs →More companies in United Kingdom →